NO20010899L - Forbedring av ugunstige apomorfin-effekter - Google Patents

Forbedring av ugunstige apomorfin-effekter

Info

Publication number
NO20010899L
NO20010899L NO20010899A NO20010899A NO20010899L NO 20010899 L NO20010899 L NO 20010899L NO 20010899 A NO20010899 A NO 20010899A NO 20010899 A NO20010899 A NO 20010899A NO 20010899 L NO20010899 L NO 20010899L
Authority
NO
Norway
Prior art keywords
apomorphine
adverse
improvement
effects
apomorphine effects
Prior art date
Application number
NO20010899A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010899D0 (no
Inventor
Ragab El-Rashidy
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of NO20010899D0 publication Critical patent/NO20010899D0/no
Publication of NO20010899L publication Critical patent/NO20010899L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20010899A 1998-08-24 2001-02-22 Forbedring av ugunstige apomorfin-effekter NO20010899L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/138,982 US5994363A (en) 1998-08-24 1998-08-24 Amelioration of apomorphine adverse effects
PCT/US1999/014965 WO2000010567A1 (en) 1998-08-24 1999-07-01 Amelioration of apomorphine adverse effects

Publications (2)

Publication Number Publication Date
NO20010899D0 NO20010899D0 (no) 2001-02-22
NO20010899L true NO20010899L (no) 2001-04-24

Family

ID=22484576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010899A NO20010899L (no) 1998-08-24 2001-02-22 Forbedring av ugunstige apomorfin-effekter

Country Status (14)

Country Link
US (1) US5994363A (de)
EP (1) EP1105129A4 (de)
JP (1) JP2002523370A (de)
CN (1) CN1212841C (de)
AU (1) AU764068B2 (de)
BR (1) BR9913235A (de)
CA (1) CA2341673A1 (de)
CZ (1) CZ2001610A3 (de)
HU (1) HUP0201212A3 (de)
IL (1) IL141512A0 (de)
NO (1) NO20010899L (de)
NZ (1) NZ510359A (de)
PL (1) PL346273A1 (de)
WO (1) WO2000010567A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
CN1471395A (zh) 2000-04-07 2004-01-28 ����ҽҩƷ���޹�˾ 阿扑***衍生物及其使用方法
CA2408399A1 (en) 2000-05-09 2001-11-15 Nitromed, Inc. Infrared thermography and methods of use
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
EP1365740A1 (de) * 2001-02-08 2003-12-03 Pharmacia Corporation Arzneizmittel mit schnellem wirkungseintritt zur behandlung von sexuellen dysfunktion
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
NZ534340A (en) * 2002-02-07 2006-04-28 Pharmacia Corp Pharmaceutical dosage form for mucosal delivery
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
JP2006504795A (ja) * 2002-10-03 2006-02-09 サイプレス バイオサイエンス， インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
KR101152183B1 (ko) 2003-03-31 2012-06-15 타이탄 파머슈티컬즈 인코퍼레이티드 도파민 아고니스트의 지속 방출을 위한 이식가능한 폴리머디바이스
EP1613323A1 (de) * 2003-04-14 2006-01-11 Vectura Limited Zubereitungen mit apomorphin zur inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US7648995B2 (en) * 2004-04-13 2010-01-19 The Mclean Hospital Corporation R(—)-11-hydroxyaporphine derivatives and uses thereof
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
US8431591B2 (en) * 2007-07-12 2013-04-30 The Mclean Hospital Corporation R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
DK2952191T3 (en) 2009-06-12 2018-12-10 Sunovion Pharmaceuticals Inc Sublingual apomorphine
CA3115378A1 (en) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Sublingual films comprising apomorphine and an organic base
EP2545905A1 (de) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited Neue therapeutische Zusammensetzung mit Apomorphin als aktiver Inhaltsstoff
EP3285771A4 (de) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Verfahren zur behandlung von morbus parkinson durch verabreichung von apomorphin an eine mundschleimhaut
IT202100009857A1 (it) 2021-04-19 2022-10-19 Univ Degli Studi Di Torino Formulazione a rilascio controllato e prolungato di apomorfina

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3976780A (en) * 1968-07-29 1976-08-24 Societe D'etudes Scientifiques Et Industrielles L'ile-De-France Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
AU1508183A (en) * 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4624965A (en) * 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
US4772459A (en) * 1986-09-09 1988-09-20 Erbamont, Inc. Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
EP0978282B1 (de) * 1994-04-22 2005-12-14 Pentech Pharmaceuticals, Inc. Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine

Also Published As

Publication number Publication date
CN1212841C (zh) 2005-08-03
IL141512A0 (en) 2002-03-10
BR9913235A (pt) 2001-12-04
HUP0201212A2 (en) 2002-08-28
EP1105129A1 (de) 2001-06-13
JP2002523370A (ja) 2002-07-30
AU4965199A (en) 2000-03-14
CA2341673A1 (en) 2000-03-02
HUP0201212A3 (en) 2004-12-28
US5994363A (en) 1999-11-30
EP1105129A4 (de) 2003-11-12
WO2000010567A1 (en) 2000-03-02
CN1324238A (zh) 2001-11-28
CZ2001610A3 (cs) 2002-03-13
NZ510359A (en) 2003-06-30
AU764068B2 (en) 2003-08-07
PL346273A1 (en) 2002-01-28
NO20010899D0 (no) 2001-02-22

Similar Documents

Publication Publication Date Title
NO20010899L (no) Forbedring av ugunstige apomorfin-effekter
ID29021A (id) Komposisi galantamina pelepasan terkontrol
PT945132E (pt) Composicao de ibuprofeno
ID27092A (id) Pembuatan ftalat anhidrida
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
ID24638A (id) Senyawa-senyawa anti aritmia bispidina
IS2325B (is) Örgerðar samsetningar epleróns
DE69941116D1 (de) G von gdf-8
NO992165D0 (no) Forbedret fremstilling av isoprenoider
CY2006003I1 (el) Χρηση δαπτομυκινης
EE200100246A (et) Asendatud fenüültsükloheksüülühendite uued esterderivaadid
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
ID24374A (id) Komposisi-komposisi parenteral alatrofloksasin
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
DE69906921D1 (de) Erweiterung des Farbtonumfangs
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
ID16838A (id) Komposisi dekafluoropentana
FI964570A (fi) Puheluiden yhdistäminen
ID24327A (id) Produksi senyawa-senyawa avermektin
PT1175417E (pt) Compostos substituidos de benzolactamas
ID23757A (id) Komposisi bahan penyempurna
ID17419A (id) Komposisi dekafluoropentana
ID23032A (id) Komposisi insektisida
FI980469A0 (fi) Arrangemang foer faestande av en begraensningsstaong vid en dragstaong

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application